

Amendments to the Claims:

Please cancel claims 1-13 and 17-22.

Please amend claims 16 and 28 as shown below.


Please add new claims 29-34 as shown below.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-15 (canceled)

16. (currently amended) A compound of the general formula I



or a salt thereof,

in which

Y represents a [halogen atom, an optionally substituted cycloalkyl, aryl, C-linked heteroaryl or heterocyclalkyl group or a] group  $-NR^1R^2$ ; where

$[R^1]$  represents a hydrogen atom or an optionally substituted alkyl, alkenyl or akynyl group;

$R^2$  represents an optionally substituted alkyl, alkenyl, cycloalkyl, aryl or aralkyl group, or]


$R^1$  and  $R^2$  together with the interjacent nitrogen atom represent an optionally substituted nonaromatic heterocyclic group [or an amino group derived from an optionally substituted amino acid ester].

Claims 17-22 (canceled)

23. (original) A pharmaceutical composition which comprises a carrier and, as active ingredient, a compound of the general formula I according to claim 16.

Claims 24-27 (canceled)

28. (currently amended) A process for the preparation of a compound of the general formula I according to claim 16 which comprises reacting a compound of the general formula II



in which Q represents a hydrogen atom or trimethylsilyl group, with a suitable halogenating agent to form a compound of the general formula I in which Y represents a halogen atom. [The process of claim 17,] further comprising reacting the compound [of general formula I] thus formed [either with a Grignard reagent of the general formula YMgX where Y is an optionally substituted cycloalkyl, aryl, C-linked heteroaryl or heterocyclalkyl group and X is a halogen atom to form a compound of general formula I in which Y represents an optionally substituted cycloalkyl, aryl, C-linked heteroaryl or heterocyclalkyl group or] with an amine of the general formula HNR<sup>1</sup>R<sup>2</sup> where R<sup>1</sup> and

$R^2$  are as defined in claim 16 to form a compound of general formula 1 in which Y represents a group  $-NR^1R^2$  where  $R^1$  and  $R^2$  are as defined above in claim 16.

29. (new) The compound of claim 16 wherein said optionally substituted nonaromatic heterocyclic group is piperazinyl, morpholinyl, thiomorpholinyl, or mopholinosulphonyl.

30. (new) The compound of claim 29 wherein said optionally substituted nonaromatic heterocyclic group is mopholinosulphonyl.

31. (new) The compound of claim 30 which is 10 $\alpha$ -(4'-(S,S-dioxothiomorpholin-1'-yl)-10-deoxo-10-dihydroartemisinin.

32. (new) The compound of claim 29 which is 10 $\alpha$ -(4'-benzylpiperazin-1'-yl)-10-deoxo-10-dihydroartemisinin.

33. (new) The compound of claim 29 which is 10 $\alpha$ -(morpholino)-10-deoxo-10-dihydroartemisinin.

34. (new) The compound of claim 29 which is 10 $\alpha$ -(1-(2-pyrimidyl)-piperazino)-10-deoxo-10-dihydroartemisinin.